Sunday, October 17, 2021 6:21:10 PM
Infections and Immune Function in Mitochondrial Diseases
Patients diagnosed with a mitochondrial disease often experience more infections that are more frequent and/or severe. In some cases, researchers and clinicians have been able to identify problems in the patient’s immune system that contribute to their infection susceptibility.
Patients with mitochondrial diseases can have issues related to the decreased production and function of the body’s white blood cells and antibodies that need to be generated to fight infection. Clinicians cannot always predict which child will manifest problems with their immune system. There are some genetic deficiencies associated with immune dysfunction, but they are not a consistent predictor of immune response problems in patients.
https://www.chop.edu/conditions-diseases/infections-and-immune-function-mitochondrial-diseases
RATIONALE: The generation of an immune response to infection requires enormous amounts of energy in the form of ATP. Children with mitochondrial disease (MD) have limited ability to produce ATP. Since ATP is generated by the mitochondria, we hypothesize that children with mitochondrial dysfunction (MD) have repeated infections due to the limited availability of ATP for the generation of a protective immune response.
METHODS: Patients with biopsy proven MD were evaluated. Clinical history, immunoglobulin subsets and subclasses, specific antibody responses, lymphocyte subsets and functional assays were analyzed.
RESULTS: Twenty-nine children (1-16 years) with MD were evaluated. Over fifty percent had repeated sino-pulmonary infections. Three (10%) had bacteremia/sepsis with Serratia sp., Pseudomonas sp., MRSA, Stenotrophomonas sp., C. tropicalis, C. albicans, C. parapsilosis and E. cloacae. Of these 3 patients, only one had a functional humoral defect and 12 episodes of bacteremia/sepsis. Ten children (34%) had hypogammaglobulinemia, and a total 3, (10%), did not respond to immunization with polysaccharide antigens. All patients had adequate distribution of CD3, CD4, CD8, CD19, and CD56 cells as well as in vitro proliferation to mitogens.
CONCLUSIONS: Children with MD exhibit immunodeficiency characterized by recurrent sinopulmonary infections and bacteremia/sepsis. It remains to be determined if this is a static defect or if the increased susceptibility to infections is related to metabolic stressors and increased ATP demands.
https://www.jacionline.org/article/S0091-6749(09)01871-5/fulltext
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
